The drug Rigosertib iv is now in a Phase 3 trial as a second line drug for higher risk MDS. This means that they have to finish the trial and that the trial should show good effects/better effects than other second line treatments for these patients. They hope that the trial will be finished in the spring 2014. Then they have to write to FDA for approval and wait for answer - that will take many months.
Then they have oral Rigosertib for lower risk MDS. This drug is only in a Phase 2 trial and we don't know when this trial and the Phase 3 trial will be finished.